Scott Thorogood is a serial CEO and entrepreneur with over 25 years of international senior management and turnaround experience, focused on life sciences, software, cybersecurity and other technology initiatives.

Thorogood is the cofounding Chairman of Nanovision Biosciences in La Jolla, CA. Nanovision has developed a breakthrough nano-scale retinal implant designed to restore sight to individuals blinded by retinal diseases such as macular degeneration. Its non-biological division is applying its image sensor technology based on a new physics discovery to low light imaging applications for DoD and commercial markets. In addition to Nanovision, Thorogood has co-founded several technology companies and served as board member and executive advisor for many other emerging growth ventures internationally, including as Chairman and founding CEO of Tradebeam (acquired by CDC /Aptean) and Oasis Inc (acquired by Sybase/SAP), as well as board observer and business advisor for Renova Therapeutics, a transformational biopharmaceutical company focused on a one-time gene therapy treatment for congestive heart failure (CHF) and type 2 diabetes. He also secured the founding investment required to launch the company. In addition, Thorogood served as executive business turnaround and technology advisor for the Canopy Group Board of Directors, a Utah based venture capital group with a large portfolio of technology companies.

Thorogood holds a BS in Mathematics and Psychology from the University of Alberta and serves as a virtual entrepreneur in residence for the Johnson Graduate School of Management at Cornell University.